NOAC plus aspirin combination therapy better than aspirin alone to reduce CV events in CAD and PAD
ESC 2017 - BarcelonaAug. 27, 2017
ESC 2017 John Eikelboom shares the COMPASS results, in which rivaroxaban plus aspirin, or rivaroxaban alone, was compared against aspirin monotherapy, for long-term secondary prevention in patients with stable CAD or PAD.
This 3-minute education provides a summary of just presented scientific data, recorded during the ESC 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.
John Eikelboom - McMaster University, Hamilton, ONT, Canada
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this 3-minute education.